It was billed as a debate on sky-high prescription drug prices — but once again, middlemen known as pharmacy benefit managers took center stage.

A panel of policy experts and biotech veterans who gathered at Harvard on Tuesday focused much of their ire on the role of insurance. Though they disagreed on plenty — like who is ultimately responsible for high drug prices — all concluded that people would probably be better off if the health care system killed copays, which some argue gives patients “skin in the game” that can keep them from using health services or drugs they don’t need.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This has to be the stupidest idea I ever heard !!!!! The PBM’s are hoping the government would do something as dumb as this !!! More for them to steal !!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy